70 studies found for:    hepatitis C | Gilead [Lead]
Show Display Options
Rank Status Study
1 Completed A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
Condition: Hepatitis C
Interventions: Drug: Single Ascending Dose Cohorts GS-9620;   Drug: Multiple Ascending Dose Cohorts GS-9620
2 Completed Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C
Interventions: Drug: GS-9669 tablets;   Drug: Placebo to Match GS-9669 tablet
3 Recruiting Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: GS-9857;   Drug: Placebo to match GS-9857
4 Completed Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: Sofosbuvir;   Drug: GS-0938;   Drug: RBV;   Drug: Placebo to match sofosbuvir;   Drug: Placebo to match GS-0938
5 Completed A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-6620;   Drug: GS-6620 tablet, 450 mg BID;   Drug: GS-6620 tablet
6 Completed GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885;   Drug: GS-9451;   Biological: peginterferon alfa-2a;   Drug: ribavirin tablet;   Drug: GS-9451 Placebo
7 Completed A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: Hepatitis C, Chronic
Interventions: Drug: Tegobuvir (GS-9190);   Drug: GS-9451;   Biological: Pegasys®;   Drug: Copegus®;   Drug: Tegobuvir placebo;   Drug: GS-9451 placebo
8 Completed GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885;   Drug: GS-9451;   Drug: tegobuvir;   Drug: placebo to match tegobuvir;   Drug: placebo to match RBV;   Drug: Ribavirin
9 Active, not recruiting A Phase 2a Study of Simtuzumab in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
Conditions: Liver Fibrosis;   Hepatitis C;   HIV;   HIV/HCV Co-infection
Intervention: Biological: Simtuzumab
10 Completed Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885 tablet;   Drug: GS-9451 tablet;   Biological: peginterferon alfa-2a;   Drug: ribavirin tablet
11 Approved for marketing Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
Condition: Post-transplant Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin;   Drug: Pegylated Interferon
12 Completed A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: Chronic Hepatitis C Infection
Interventions: Drug: GS-9190;   Drug: GS-9256;   Biological: Pegasys®;   Drug: Copegus®;   Drug: GS-9190 placebo;   Drug: GS-9256 placebo
13 Completed A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Conditions: Hepatitis C,;   Human Immunodeficiency Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
14 Completed A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Conditions: Chronic Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
15 Completed Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India
Conditions: Hepatitis B;   Hepatitis C
Intervention:
16 Active, not recruiting An Open-Label Study to Explore the Clinical Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Conditions: Hepatitis C;   Hepatocellular Carcinoma
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin
17 Completed Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: Sofosbuvir;   Drug: EFV/FTC/TDF;   Drug: EFV;   Drug: ZDV/3TC;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: DRV;   Drug: RAL;   Drug: PEG;   Drug: RBV
18 Completed
Has Results
Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
Condition: Hepatitis C, Chronic
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
19 Completed GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885;   Drug: Tegobuvir;   Drug: GS-9451;   Drug: ribavirin tablet
20 Terminated GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
Condition: Chronic Hepatitis C
Interventions: Drug: GS-5885;   Drug: GS-9451;   Drug: RBV;   Drug: PEG

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years